Emran Lyutfi

Emran Lyutfi

Auto-generated profile, based on publicly available information

Emran Lyutfi

Medical University of Varna

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2022 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
GSGeorge Stoyanov Stoyanov
George Stoyanov Stoyanov
ELEmran Lyutfi
Emran Lyutfi
RGReneta Georgieva
Reneta Georgieva
RGRadoslav Georgiev
Radoslav Georgiev
DDDeyan Dzhenkov
Deyan Dzhenkov
PGPeter Ghenev
Peter Ghenev

30 April 2023 in Bulgarian Neurology
Verified
Journal Article
Open access
PDF file
КГКристиян Георгиев
Кристиян Георгиев
ЕЛЕ. Лютфи
Е. Лютфи
НСН. Сюлейман
Н. Сюлейман
ДГД. Георгиева
Д. Георгиева
БИБ. Иванов
Б. Иванов
АКА. Капрелян
А. Капрелян
Рекурентнатата болезнена офталмоплегична невропатия (РБОН) е форма на краниална невралгия и рядко наблюдавана причина за главоболие. В литературния обзор представяме историята на диагнозата и съвременните схващания за появата и диагностицирането на РБОН. В клиничният случай представяме пациентка, многократно хоспитализирана в клиниката с пристъпи на главоболие, придружени със симптоми от различни краниални нерви, с най-често засягане на очедвигателните.

8 April 2025 in Scripta Scientifica Medica
Verified
Journal Article
Closed access
PDF file
BDBora Dogan
Bora Dogan
ELEmran Lyutfi
Emran Lyutfi
BIBorislav Ivanov
Borislav Ivanov
AKAra Kaprelyan
Ara Kaprelyan
Myasthenia gravis (MG) is a rare autoimmune disorder characterized by an antibody-mediated neuromuscular transmission block, leading to skeletal muscle weakness and fatigue. Epilepsy, a condition of unprovoked, recurrent seizures, rarely coexists with MG. Recent studies indicate an elevated epilepsy risk in patients with autoimmune diseases, including MG, potentially linked to autoimmune mechanisms or long-term anticonvulsant use. We report a 73-year-old woman diagnosed with MG, treated with pyridostigmine, with complaints of difficulty swallowing, excessive salivation, drooping eyelids, increased fatigue in the arms and legs, and with three generalized tonic-clonic (GTC) seizures in the past year, each lasting 1–2 minutes. The most recent seizure occurred a week before hospitalization. Neurological examination revealed bilateral ptosis, increased limb fatigue, and dysphagia. Electromyography (EMG) confirmed postsynaptic neuromuscular damage consistent with MG. electroencephalography (EEG) demonstrated epileptiform activity. This case highlights the rare but clinically significant coexistence of MG and epilepsy, emphasizing the need for thorough neurological assessment in MG patients with seizure-like episodes. Recognizing epilepsy in MG is crucial for appropriate treatment and improved patient outcomes. Further research is needed on autoimmune comorbidities in neurological disorders.

1 September 2022 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
ELE Lyutfi
E Lyutfi
GSGeorge Stoyanov Stoyanov
George Stoyanov Stoyanov
DDDeyan Dzhenkov
Deyan Dzhenkov
BIB D Ivanov
B D Ivanov
AKA Kaprelyan
A Kaprelyan
KGK Georgiev
K Georgiev
Glioblastoma (GBM) is the most common malignant primary central nervous system (CNS) tumor. It is a fast-growing and extremely aggressive malignancy with a short postoperative survival time of little more than a year. The tumor-immune system interactions are complex and can be measured as local phenomena - e.g., tumor-infiltrating lymphocytes, or as systemic events - e.g., lymphopenia, neutropenia, etc. with cell numbers allowing for estimation of the type of immune reaction against the tumor. A retrospective non-clinical approach was utilized for the means of the study. Patients with a histologically and molecular verified GBM, corresponding to the guidelines of 2021 WHO CNS tumor classification, diagnosed in a three-year interval (February 2018-2021) in a single tertiary healthcare institution were included. Patients with infectious, inflammatory, autoimmune, and hematological diseases, as well as those with malignancy in another location, were excluded. Data regarding patient demographics, and preoperative peripheral blood cell counts (neutrophils, platelets, and monocytes in a ratio to lymphocytes) were compared with postoperative patient survival. Preoperative ratios were calculated as absolute values. For cutoff values we used generally accepted ones - >4 for neutrophil to lymphocyte (NLR), >200 for thrombocyte to lymphocyte (TLR), and >0.25 for monocyte to lymphocyte ratios (MLR). Results were statistically analyzed with MedCalc version 19.7.1 and the Kaplan-Meier method. A total of 22 patients fit the established criteria, with a male to female ratio of 2.14:1, mean age of 66.23 years, and mean survival of 255.72 days (8.04 months, range 24-801 days). Eight patients had an elevation of NLR and five of PLR, with no statistical correlation to survival. Six patients had an increase in MLR with a statistically significant (p=0.0044) shorter postoperative survival. Synergic increase in NLR and PLR did not show significance, while synergic increase with MLR showed no added benefit, as did comparison within MGMT promoter methylation groups. Elevation in NLR, PLR, and MLR is a good independent prognostic marker for postoperative patient survival in histologically and mutationally verified GBM. * contributed equally to the work and should be considered co-first authors.Financing: Medical University - Varna Scientific Fund, grant number 19010 and National scientific fund - young researchers (Republic of Bulgaria) grant number 2990/07.06.2021 Ethical approval: Medical University - Varna committee on scientific ethics approval protocol number 93/21.05.2020